Search clinical trials for: BI 11634 IR tablet

Total 112 results

Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy
Bausch Health Americas, Inc.

Completed

Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis

Liver Cirrhosis

United States, Russian Federation
MapLight Therapeutics

Enrolling by invitation

ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Canada, Australia
Stallergenes Greer

Completed

Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis

Allergy
Stallergenes Greer

Completed

Safety and Efficacy on Phase III Study on 300 IR SLIT to Patients Suffering From Grass Pollen Rhinoconjunctivitis

Primary Disease

France, Italy, Spain
Stallergenes Greer

Completed

Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis

Allergic Rhinitis Due to Grass Pollens

United States
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
GlaxoSmithKline

Completed

Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib

Cancer

Australia
Stallergenes Greer

Completed

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Allergy

Germany
Stallergenes Greer

Completed

Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Seasonal Allergic Rhinitis

Austria
Alexion Pharmaceuticals, Inc.

Completed

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
Daewon Pharmaceutical Co., Ltd.

Completed

Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects

Healthy
MapLight Therapeutics

Recruiting

ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Autism Spectrum Disorder

United States, Australia, Canada
Bristol-Myers Squibb

Completed

A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Stallergenes Greer

Completed

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

Allergic Rhinitis
Stallergenes Greer

Completed

Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Allergy

France
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Migraine Disorders

Belgium, Germany
Kowa Research Institute, Inc.

Completed

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

Healthy

United States
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Nanoform Finland Plc

Completed

PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects

Pain

United Kingdom
Grünenthal GmbH

Completed

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Pain | Chronic Pain | Neuropathic Pain | Visceral Pain

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How the Body Takes up and Tolerates Different Doses of BI 474121, and Whether it Makes a Difference if BI 474121 is Taken as a Tablet or a Drink.

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers

Healthy
Pfizer
Medivation, Inc.

Completed

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Huntington Disease | Alzheimer's Disease

United States
Medical University of Vienna
Merck Serono GmbH, Germany

Active, not recruiting

Metformin Therapy in Non-diabetic AAA Patients (MetAAA)

Abdominal Aortic Aneurysm

Austria
Boehringer Ingelheim

Completed

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Healthy

Germany
Mylan Inc.
Mylan GmbH

Completed

Mylan Insulin Glargine Study

Diabetes Mellitus, Type 1

United States
AstraZeneca
Bristol-Myers Squibb

Completed

To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately

Type 2 Diabetes Mellitus

United Kingdom
Bayer
Merck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)

Chronic Heart Failure With Preserved Ejection Fraction

Spain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
Boehringer Ingelheim

Completed

Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects

Healthy
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Bayer

Completed

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Pharmacokinetics

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Healthy

3

Subscribe